IL6 and congenital rubella syndrome: The specific mechanism of cardiovascular adverse reactions in CAR-T treatment is not precise, and the potential mechanisms (Figure 3) include: 1) severe CRS results in hemodynamic instability, capillary leakage, and DIC, and increased serum concentrations of VWF and Ang-2 (Hay et al., 2017); 2) IL-6 is a crucial cytokine leading to CAR-T therapy-related CRS, and a significant increase in IL-6 is closely related to adverse cardiovascular reactions (Stein-Merlob et al., 2021).